Two large cannabis companies, Aphria and Tilray, are in advanced talks to merge. An announcement was made this week and reported on widely. The company resulting from this merger would retain the name of the Tilray company, and its CEO would be Aphria’s current CEO, Irwin Simon. Negotiations between the two companies are currently underway, with no guarantee that an agreement will be reached.
Two large Canadian cannabis companies, Aphria and Tilray, are in advanced talks to merge. An announcement was made this week and reported on widely.
The company resulting from this merger would retain the name of the Tilray company, and its CEO would be Aphria’s current CEO, Irwin Simon. Negotiations between the two companies are currently underway, with no guarantee that an agreement will be reached.
A giant of the cannabis industry
If the negotiations are successful and there is a business merger, the resulting company would have a combined market cap of nearly $4 billion. What’s more, it would become the world’s largest global cannabis company by turnover according to the companies’ joint press release.
The mega-cannabis industry would operate in markets such as the US, Canada, Portugal and Germany. It would also be well-positioned in Europe to undertake more projects in more countries.
Big interests in the merger
Currently, the Tilray company has a production plant in Portugal and is also present in Australia, Germany, and the United Kingdom. On the other hand, Aphria has pharmaceutical distribution activities in Germany.
The result of this merger of Canadian companies would be control of almost 20% of the Canadian recreational market with an annual turnover of $930 million.
The merger is expected to save both companies about $100 million annually. The Aphria company would be able to produce the majority of the resulting entity’s Canadian cannabis inventory, using its huge 12-hectare greenhouse. This would allow Tilray to liquidate its facilities in the country.
Another interesting aspect of the merger would be that the presence in the United States market would be greatly strengthened. In fact, cannabis sales have had an acceleration during the current pandemic.
The combined company will not yet be able to operate there insofar as actually ‘touching the plant,’ “But when (US) legalization occurs,” said Aphria CEO Irwin Simon, “when we have the best in class in Canada, the best in class in Europe … and have a business in the US market, be domiciled in the US market, the opportunity to buy something, create something, will be within reach to go ahead and do it.”
The cannabis company will look for new acquisition options
The new CEO of the resulting entity, Irwin Simon, also said he would consider seeking new acquisition opportunities.
Tylray CEO Brendan Kennedy, on the other hand, said he believed it was more than “extremely likely” that all European Union countries would legalize medical cannabis within two years. The recent reclassification of cannabis by the UN will be its accelerator.
“There are tremendous growth opportunities, not only in the existing European market, but also in new markets, medically, like France,” said Brendan Kennedy. “I think that will lead to more talk about legalizing adult use in Europe, which will happen not only in 2021, but in the years to come.
A second attempt by cannabis company Aphria
This is the second time that Aphria has discussed agreements between companies in the sector. BNN Bloomberg last July already reported that the company giant entered into negotiations with another company—in this case, Aurora Cannabis Inc. These talks were later broken off when no agreement was reached on compensation and board composition resulting from that possible merger.
Another major difference between these two companies was that Tilray generated almost half of its hemp food products business with Manitoba Health. “This would appeal to Aphria given Simon’s previous role as head of the organic food operator Hain Celestial Group Inc, and could add steady revenue to its non-Cannabis subsidiaries, such as German pharmaceutical distribution company CC Pharma and Sweetwater Brewing.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in La Marihuana, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.